Plavix (Clopidogrel)
Brand Names: Plavix
Methodology & AI Transparency ⓘ
Plavix (Clopidogrel) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active moiety Clopidogrel (cross-referenced at /meds/clopidogrel) and registered by Sanofi-Aventis U.S.
- 2 Real-world patient consensus: Commercial Plavix monograph (75 mg/1 Tablet, Film Coated) cross-indexed with generic Clopidogrel for therapeutic equivalence review.
- 3 Typical cash cost range: Public pharmacy ledger: $5.84 low cash benchmark vs. $34.50 chain retail average ($8.1761/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Plavix (Clopidogrel) include nausea (7.6%), headache (6.6%), dizziness (5.9%).
Ask our AI Specialists anything about Plavix (Clopidogrel)
Plavix (Clopidogrel) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active moiety Clopidogrel (cross-referenced at /meds/clopidogrel) and registered by Sanofi-Aventis U.S. LLC, Plavix operates as a prescription brand-name p2y12 platelet inhibitor therapy (RxNorm 213169; NDC 0024-1171, 0024-1332). Under 2025-05-30 FDA labeling for 75 mg/1 Tablet, Film Coated; 300 mg/1 Tablet, Film Coated, Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome – For patients with non–ST-segment elevation.
Bioactive Clopidogrel within Plavix governs p2y12 platelet inhibitor target modulation involving CYP2C19 clearance pathways. Commercialized across 75 mg/1 Tablet, Film Coated; 300 mg/1 Tablet, Film Coated (registered by Sanofi-Aventis U.S. LLC, SPL 2025-05-30), Plavix combines branded dosage-form consistency (NDC 0024-1171, 0024-1332) with transparent cash-pay comparisons spanning $5.84 to $34.50.
Clinical clearance of Plavix (Clopidogrel) (P2Y12 Platelet Inhibitor) relies on biotransformed through cyp2c19 pathways with mixed urinary/fecal clearance with a Mean elimination half-life of 4 to 10 hours across adult Plavix (Clopidogrel) dosing half-life; patients absorbing at Oral fraction absorbed ranges from 67% to 79% (Plavix (Clopidogrel) 75) bioavailability typically observe target onset around oral tmax achieved within 2 to 5 hours following plavix (clopidogrel) ingestion.
FDA clinical labeling for Plavix (Clopidogrel) restricts administration in previous anaphylactoid or exfoliative reaction attributed to plavix (clopidogrel); clinical scenarios where p2y12 platelet inhibitor exposure from plavix (clopidogrel) poses unacceptable risk across 75 mg/1 Tablet, Film Coated, 300 mg/1 Tablet, Film Coated, 75mg Tablet, with self-reported patient tracking dominated by nausea (7.6% of reports), headache (6.6% of reports), dizziness (5.9% of reports).
Prothrombin time and INR stability may fluctuate when Plavix (Clopidogrel) is added to chronic warfarin regimens.
Systemic bioavailability and half-life of Plavix (Clopidogrel) respond to strong CYP2C19 enzymatic inhibition or induction.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Plavix (Clopidogrel)
- Clinical scenarios where p2y12 platelet inhibitor exposure from Plavix (Clopidogrel) poses unacceptable risk
Logged Side-Effect Incidence (22 Reports)
Plavix (Clopidogrel) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Plavix (Clopidogrel))
Human clinical trial evidence for Plavix (Clopidogrel) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Plavix (Clopidogrel) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $8.1761/unit (~$245.28/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $5.84 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $7.50 / mo | View logs ↓ |
Plavix (Clopidogrel) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Plavix (Clopidogrel) RxNorm Concept ID | 213169 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $8.1761 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $5.84 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 75.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Plavix (Clopidogrel) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Plavix (Clopidogrel): FDA labeling (2025-05-30, NDC 0024-1171), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Plavix (Clopidogrel) community threads and patient logs by age, biological sex, dosage, and treatment duration.